INTRODUCTION
With increasing age, the incidence of hematological malignancies rises, including myelodysplastic syndrome (MDS). MDS is characterized by ineffective hematopoiesis, a defect of differentiation in one or more hematopoietic lineages, which can progress to acute myeloid leukemia (AML) in time 1, 2 . Throughout the development of MDS and AML, a vast subset of different driver mutations can be identified that are prognostic for disease outcome. In low-risk MDS, frequently one driver mutation can be recognized which is accompanied by a second mutation in the context of disease progression 2, 3 . Two genes that are found to be comutated in MDS and AML patients are ASXL1 and TP53 4, 5 . Mutations altering or disabling TP53 can be missense mutations, frameshift mutations, or loss of the short arm of chromosome 17, where the TP53 gene is located 6, 7 . The role of p53 in cell fate decisions makes it an attractive target for functional inactivation of its signaling pathways in cancer 8, 9 . Functional knockout studies of the mouse TP53 gene, Trp53, revealed early spontaneous tumors and resistance to apoptosis after induced DNA damage 10, 11 . In patients, TP53 mutations are mainly found in complex karyotype MDS and AML with unfavorable prognosis 4, 12 . Mutations in ASXL1 are also generally associated with an unfavorable prognosis 13 . ASXL1 is an epigenetic modifier and mutations of it may lead to the truncation of its protein thereby disrupting the chromatin interacting and modifying domain. One of the main functions of ASXL1 is its interaction with the polycomb repressive complex 2 (PRC2). The PRC2 complex is stabilized and/ or recruited to the histone 3-lysine 27 by ASXL1, leading to trimethylation and thereby repression of certain loci 14 . Loss of function of ASXL1 in mice has been found to be embryonic lethal and after long latency, ASXL1 heterozygous mice developed MDS-like phenotypes [15] [16] [17] . Additionally, ASXL1 loss leads to reduced numbers of erythroid progenitors in vitro and in vivo, accompanied by increased apoptosis and decreased H3K27me3 levels 18, 19 . Nevertheless, malignant transformation has only been observed in cells with altered genetic background, suggesting that ASXL1 mutations need to be accompanied by additional mutations 14 .
In this study, we addressed whether simultaneous loss of ASXL1 and TP53 in human hematopoietic stem and progenitor cells (HSPC) can rescue the negative phenotype in the erythroid lineage upon ASXL1 knockdown and promote transformation. We used an RNAi approach to reduce gene expression of both genes independently. The obtained results demonstrate a growth advantage of shTP53/shASXL1 cells over shASXL1 single cells in vitro but without malignant transformation in vivo.
METHODS AND MATERIALS

Primary cell isolation
After informed consent was obtained in accordance with the Declaration of Helsinki, CD34
+ cord blood cells (CB) were isolated from the University Medical Center Groningen and the Obstetrics departments at the Martini Hospital, Groningen, The Netherlands. The AutoMacs (Miltenyi Biotec, Amsterdam, The Netherlands) was used to purify CB CD34 + cells.
Cell culture
CB CD34 + cells were grown under erythroid permissive conditions in DMEM (Westburg, Leusden, The Netherlands) supplemented with 12% FCS, 10 mg/mL bovine serum albumin, 1% pen-strep, 1.9 mM sodium bicarbonate, 1 µM b-estradiol, 1 µM dexamethasone, 0.1 mM 2-mercaptoethanol, 0.3 mg/mL rHu Holo-Transferrin (Sigma, city country), 40 ng/ mL rHu IGF-1 (Sigma), 20 ng/mL SCF, 5 U/mL rHu EPO. Cells were also cultured under myeloid liquid conditions (IMDM supplemented with 20% FCS (Sigma, Zwijndrecht, The Netherlands), 1% pen-strep, interleukin 3 (IL-3; Gist-Brocades, Delft, The Netherlands), and stem cell factor (SCF, Amgen,Thousand Oaks, USA)).
Long-term cultures on stroma
Long-term cultures were performed as previously described 20 . Using MS5 stromal cells, CB CD34
+ cells were expanded in long-term culture (LTC) medium (Gartner's) (αMEM supplemented with 12.5% heat-inactivated horse serum, 12.5% heat-inactivated FCS, 1% pen-strep, 1μM hydrocortisone (Sigma) and 57.2 μM β-mercaptoethanol (Sigma)), with or without cytokines (SCF (20ng/mL)) and EPO (2U/mL)). Cultures were grown at 37°C and 5% CO 2 .
CFC assays
For colony forming cells (CFC) assays, GFP + CD34 + cells were plated in duplicate in 1 mL methylcellulose (H4230, Stem Cell Technologies, city country) supplemented with 20ng/ mL IL-3, interleukin-6, SCF, recombinant Human granulocyte-colony stimulating factor (G-CSF), Flt-3L, 10ng/mL granulocyte macrophage (GM)-CSF, and 1U/mL Epo. Colonies were scored within 10 to 14 days after plating.
Mouse Experiments
The humanized ectopic bone model was created as previously described 21, 22 . Briefly, four hybrid scaffolds consisting of three 2-3mm biphasic calcium phosphate (BCP) particles engulfed in human MSCs were implanted subcutaneously into female NSG mice. Eight 3 weeks after scaffold implantation, 4,5x10 4 transduced CD34+ cells were directly injected into three of the four scaffolds.
Lentiviral transductions
The lentiviral short hairpin RNA vector of human ASXL1 was a generous gift from prof. dr. Giovanni Morrone (University of Catanzaro Magna Graecia, Catanzaro, Italy). ASXL1 hairpins target the following sequences (1) GCTATGTCACAGGACAGTAAT and (2) CCAGGAGAATCAGTGCGTATA. The ASXL1 hairpin was cloned from a puro vector into the pLKO.1 lentiviral vector containing mCherry by cutting the restrictions sites with MUNI and SACII. As control, a pLKO.1 mCherry vector containing a scrambled (SCR) short hairpin was used. The TP53 hairpin targets the following sequence GACTCCAGTGGTAATCTACT and was cloned into a pHRTrip GFP vector. Lentiviral particles were produced by using the Fugene transfection system (Promega, Madison, WI, USA) together with the packaging construct PAX2, glycoprotein envelope plasmid VSV-G, and construct of interest. 293T cells were then transiently transfected and stable transduction of cell lines or CB CD34 + cells was performed. Transduction efficiencies were measured by fluorescence-activated cell sorter (FACS) analysis. Knockdown was verified by real-time polymerase chain reaction and Western blot.
Flow cytometry analysis
The following antibodies were used: brilliant violet anti-CD45 (H130, Biolegend, Alphen a/d Rijn, The Netherlands), allophycocyanin (APC)-conjugated anti-CD34 (581, BD Biosciences, Alphen a/d Rijn, The Netherlands), phycoerythrin (PE) anti-CD14 (HCD14, Biolegend), pacific blue (PB)-conjugated anti-CD15 (W6D3, Biolegend), brilliant violet anti-CD71 (M-A712, BD), R-PE anti-Glycophorin-A ( JC159, Dako, Heverlee, Belgium). All cells were blocked with anti-human FcR block (Stem Cell Technologies) and murine cells were additionally blocked with anti-mouse Fc-γ (BD). Cells were then incubated with antibodies for 30 minutes at 4°C. All FACS analyses were performed on a FACS LSR-II, cells were sorted on a MoFlo-XDP or -Astrios (DakoCytomation, Carpinteria, CA, USA) and data were analysed using FlowJo vX.0.7.
RESULTS
Double loss of ASXL1 and TP53 rescues replating potential of HPSC
To delineate the role of ASXL1 and TP53 loss in hematopoiesis, we used an RNAi approach. We performed knockdown of control vectors (shSCR/shSCR, hereafter called control), knockdown of ASXL1 alone (shSCR/shASXL1, hereafter named shASXL1), knockdown of TP53 alone (shTP53/shSCR, hereafter called shTP53), or double knockdown (shTP53/ shASXL1). We transduced CD34
+ cord blood cells in triplicates, sorted double transduced cells and confirmed knockdown with qRT-PCR and western blot (Fig 1A, S1A) . Additionally, knockdown of an independent set of hairpins was conducted and verified (S1B). Efficacy of transduction efficiency was equal among hairpins, as shown in S1C.
We previously observed that knockdown of ASXL1 decreases colony forming potential due to enhanced apoptosis 18 . To demonstrate whether downregulation of p53 can counteract this phenotype, we co-transduced CD34 + CB cells with shTP53 in the context of shASXL1. CD34 + cells were sorted and plated into a colony-forming assay, allowing for colony formation within 14 days (Fig 1B, S1D) . Upon replating, granulocytic colony formation of the TP53/ASXL1 double knockdown was enhanced four-fold when compared to the control (hairpin #1 p<0.01, hairpin #2 p<0.001), and more than three-fold when compared to ASXL1 and TP53 single knockdown (hairpin #1 p<0.05, hairpin #2 p<0.001). In addition, long-term suspension cultures were used to study the phenotypes of ASXL1 and TP53/ ASXL1 cells. Throughout time, shASXL1 cells revealed diminished growth compared to control cells (Fig 1C) , which could partially be rescued by down-regulation of TP53. Error bars represent standard deviation; *p<0.05; **p<0.01; ***p<0.001 more granulocytic colonies than shASXL1 (p<0.05) and control cells (Fig 1D) . When looking at gene expression at day 7, ASXL1 and TP53 were significantly down-modulated but downstream targets such as p21 and Bax were not significantly changed (S2B).
Subsequently it was studied whether comparable results can be obtained if the transduced cells were cultured in the context of a stromal microenvironment. Therefore, long-term stromal cultures with a MS5 stromal layer were initiated (Fig 1E) . A comparable degree of expansion was observed in the different subgroups of transduced cells. FACS analyses of double TP53/ ASXL1 and ASXL1 single knockdown cells in suspension showed comparable CD14/CD15 percentage, as well as similar cell numbers over time (S2C, week 2 and 3). However, CFC formation in time demonstrated a strong decline of CFU-GM numbers in the shASXL1 cells, which could partially be rescued by down-regulation of p53, in particular of the granulocytic lineage ( Fig 1F, week 3 , p<0.01). To demonstrate these findings in more detail the longterm culture initiating cell (LTC-IC) assay was used as a read-out for the ability of primitive progenitors to form colonies after an extended period in culture (Fig 1G) . The data clearly shows that loss of ASXL1 significantly reduces the cobblestone forming potential (control vs shASXL1, p<0.05) and additional knockdown of TP53 restores the phenotype.
Taken together, these data suggest that an additional knockdown of TP53 with ASXL1 gives an advantage for progenitors in suspension. Moreover, TP53 loss rescues the detrimental effect of ASXL1 loss on primitive progenitors and their ability to adhere to the bone marrow in vitro and thereby restores primitive progenitors to similar numbers as control cells.
TP53 knockdown partially rescues adverse shASXL1 induced apoptotic phenotype of erythroid cells
To demonstrate whether similar findings can be observed of the erythroid lineage, CB CD34 + cells were transduced and cultured under erythroid permissive conditions. Persistent during culturing, shTP53/shASXL1 cells had a growth advantage over shASXL1 cells (Fig 2A) . On day 24, cells with a double knockdown had similar cumulative cell count to control cells and a significantly higher cell count than ASXL1 single cells (p<0.05). The knockdown of ASXL1 was accompanied with an increase in Annexin V + , which was rescued with additional knockdown of TP53 (Fig 2B, day 10 , shSCR/shASXL1 vs shTP53/shASXL1, p<0.05). mid cells compared to controls and shTP53 cells (Fig 2C, p<0.05) . The apoptotic phenotype of ASXL1 single knockdown was significantly and transiently rescued within the CD71 mid compartment (Day 10, shSCR/shSCR vs shTP53/shASXL1, p<0.05) and CD71 bright (shSCR/shASXL1 vs shTP53/shASXL1 p<0.01) (Fig 2C, S3A) . Total cell numbers of shTP53/shASXL1 erythroid differentiating cells were unchanged when compared to shASXL1 single (S3B). A stable reduction in gene expression was observed in time (Fig 2D) . Furthermore, reduction of ASXL1 was associated with the up-and down-regulation of HOXA9, BNIP3L, GATA2, and PIM1 (Fig 2E) . Additional knockdown of TP53 rescued loss of gene expression only for GATA2 and PIM1. When looking at potential p53-related genes that could be involved in the rescue (Day 7), only BCL-2 appeared to be significantly changed (Fig 2E) . The direct downstream targets DAPK, BAX and PUMA did not display significantly altered gene expression (S3C). These findings suggest that the favorable phenotype of shTP53/shASXL1 is not due to an increase in total cell numbers but rather due to reduced apoptosis and enhanced cell survival.
Bone marrow microenvironment in vitro gives partial growth advantage but does not alter cell fate of shTP53/shASXL1 erythroid cells
The double knockdown of ASXL1 with TP53 led to a partial rescue of erythroid differentiating cells under liquid permissive cultures. We therefore investigated whether erythroid cells would receive additional benefits from a bone marrow microenvironment. Cells were transduced and grown on MS5 stromal cells with the addition of EPO and SCF to stimulate cell development and differentiation along the erythroid lineage. The double knockdown permitted a growth advantage over ASXL1 loss alone (Fig 3A, day 14, p<0 .05) and double loss of ASXL1 and TP53 was accompanied by a significant reduction in apoptosis when compared to ASXL1 knockdown (Fig 3B, Day 10, p<0.05 ). Throughout culturing, shTP53/ shASXL1 cells exposed a greater percentage of CD71 mid than compared to shASXL1 cells (S3A, Fig 3C, day 10&14) with a consistently higher cell number (S4B). At day 14, shTP53/ shASXL1 cells had a significantly lower percentage of GPA + compared to control, which was similar to shASXL1. Annexin V stainings conducted within the differentiation compartments revealed lower apoptosis of shTP53/shASXL1 compared to shASXL1 cells (Fig 3C) . This data suggests that intrinsic cues are responsible for the negative phenotype of the ASXL1 cells and extrinsic cues of the microenvironment affect the erythroid differentiation. Error bars represent standard deviation; *p<0.05; **p<0.01 
Humanized bone marrow-like niche in the mouse does not lead to transformation of cells with double knockdown
The incomplete rescue of ASXL1 by an additional loss of TP53 cultured on MS5s may be partly due to the lack of a supportive microenvironment or due to a limited exposure time. Our lab previously proved that using a scaffold setting in vivo leukemic properties are better maintained within a human niche than a mouse niche 21 . We therefore argued that a human microenvironment within a mouse may be optimal for cell survival and possibly malignant transformation. To this end, we transduced CD34 + CB cells with shTP53/shASXL1, injected them directly into three scaffolds per mouse, bled the mice in intervals and sacrificed after 48 weeks (Fig 4A) . Remaining transduced CD34 + CB cells were sorted to determine knockdown efficiency. Figure 4B shows the sorting gates, which were equally divided between the double knockdown and the ASXL1 single knockdown. 
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Comparing knockdown efficiencies of the obtained RNA internal repeats show a significant knockdown for ASXL1 and TP53 within the groups (Fig 4C) . Engraftment of human CD45 + cells was low throughout maturing of the mouse and declined after 34 weeks (Fig  4D) . After sacrificing, bone marrow, spleen and liver were examined for human engraftment, and the TP53 (GFP)/ASXL1 (mCherry) percentage in the bone marrow, liver and spleen was analyzed (Fig 4E) . FACS data suggested that GFP and mCherry double positivity was mostly due to auto fluorescence (Fig 4F) , suggesting that a combined knockdown of ASXL1 and TP53 is inefficient in allowing for long-term engraftment and subsequently malignant transformation. Additionally, scaffolds were embedded and examined for the presence of CD45 + cells (Fig 4G) . Few human CD45 + cells could be found within the scaffolds, suggesting that cells with a double knockdown of ASXL1 and p53 did not benefit from the human bone marrow microenvironment.
DISCUSSION
ASXL1 has critical function in the up-make of the hematopoietic compartment whereby loss of function is associated with embryonic lethality at high frequency. Heterozygous mice have a milder phenotype and can develop a MDS-like phenotype but only in the presence of an comutation such as TET2 or in the background of NRAS12GD 14, 15 . In healthy individuals ASXL1 mutations can also be demonstrated in low-frequency but without displaying a malignant phenotype 23, 24 . Many of these persons present with clonal hematopoiesis of indeterminate potential (CHIP) where clones with a mutation of one leukemogenic gene demonstrate preferential expansion 25, 26 . However, current studies suggest that additional mutations are necessary for CHIP to progress into MDS or AML. TP53 is, like ASXL1, often present in CHIP 27 . A co-mutation of both genes is frequently observed, implying that hematopoietic clones have a selection benefit and may contribute to MDS and/or AML development.
In this study, we investigated the loss of ASXL1 alone and in combination with TP53 knockdown. We observed a strong apoptotic effect of ASXL1 knockdown on cell proliferation and differentiation, specifically along the erythroid lineage but without triggering malignant transformation. Furthermore, colony formation and stem cell frequency was impaired. Additional knockdown of TP53 restored stem cell frequency of shASXL1 cells to normal levels and had an overall beneficial effect on HSPC development. In vivo studies showed that the adverse effects of ASXL1 loss on HSPCs were too dominant and additional loss of TP53 was not sufficient to allow for engraftment of cord blood cells and malignant transformation. Recent studies of clonal evolution in MDS have demonstrated that ASXL1 and TP53 frequently co-occur in high-risk MDS but that also additional mutations emerge during malignant transformation 4, 28 . We have shown that in general cells benefit from a combined knockdown of TP53 and ASXL1 versus single knockdown of ASXL1. Conversely, highrisk MDS patients can present with three mutations or more suggesting that two mutations might be too limited to recapitulate the full spectrum of malignant transformation in human HPSC 29, 30 . Moreover, the type of ASXL1 and TP53 abrogation may also be of importance. Many mouse studies have shown that loss of TP53 leaves mice prone to develop tumours 10, 31 . Lack of evidence that a mutated ASXL1 protein is functional suggested that a RNAi approach might be an appropriate way to mimic patient setting. However, recent studies have shown that overexpressed mutated ASXL1 proteins are capable of acting within the PR-DUB pathway and globally erase and diminish H2AK119ub and H3K27me3, respectively 32, 33 . Similarly, TP53 mutations are also associated with loss of function. However, new studies have demonstrated that mutated TP53 protein can also gave additional functions by directly targeting chromatin modifiers and by affecting the proteasome gene transcription 34, 35 . Therefore, a combined knockdown of ASXL1 and TP53 may not reflect the total mutational status as observed in MDS and AML. Furthermore, the order of mutation may play crucial role in what phenotype cells present with. Ortmann et al. discovered that TET2 mutations preceding JAK2 V617F heavily influenced the JAK2 V617F activated transcriptional program 36 . The order of mutation appeared to be of such importance that it affected the clonal evolution in patients.
In our mouse model, we observed a lack of engraftment in part due to lack of expansion of cells. A study conducted by Wong et al suggests that additional external cues are necessary to allow for increased cells expansion 37 . They demonstrated in their mouse model that TP53 mutated HSPCs revealed preferential expansion after exposure to chemotherapy treatment, leading to therapy-related AML and MDS
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. While the human bone marrow niche is capable of maintaining leukemic cell properties it may not be sufficient for ASXL1/ TP53 transforming myeloid cells without an additional stress factor. In summary, our data demonstrate that ASXL1 compromised cells benefit from loss of TP53 but do not lead to malignant transformation. 
